Highlights ABIONYX Pharma Börse Stuttgart

Equities

609 FR0012616852

Market Closed - Börse Stuttgart Other stock markets 07:31:47 07/06/2024 pm IST			5-day change	1st Jan Change
1.146 ^EUR	-1.72%		-1.72%	-36.40%

14/03	Abionyx Pharma: to benefit from a 1ME grant from Bpifrance	CF
11/03	Abionyx: reduced net loss in 2023	CF

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Abionyx Pharma: to benefit from a 1ME grant from Bpifrance	14/03	CF
Abionyx: reduced net loss in 2023	11/03	CF
ABIONYX Pharma SA Reports Earnings Results for the Full Year Ended December 31, 2023	11/03	CI
Abionyx: CSL Behring fails in heart disease trial	16/02	CF
ABIONYX Pharma SA Acknowledges the Clinical Results of the Phase 3 Aegis-Ii Study Evaluating the Efficacy and Safety of Csl Behring?S Human-Plasma-Derived Apoa-I, CSL112	15/02	CI
ABIONYX Pharma Presents Preclinical Results for CER-001 in Brain Fog, At the 1st International Scientific Congress on Brain-Kidney Interaction in Naples on November 23-24, 2023	24/11	CI
ABIONYX Pharma Announces New Positive Results in a Uveitis Model for the Strategic Development of the First Class of Biomedicines in Ophthalmology Based on its Recombinant apoA-I	21/11	CI
Abionyx Pharma Racers Study Data in Sepsis Presented At the American Society of Nephrology 2023 Annual Meeting "Kidney Week"	02/11	CI
ABIONYX Pharma RACERS Study in Sepsis Selected for Late-Breaking Clinical Results Poster Presentation at the American Society of Nephrology 2023 Annual Meeting " Kidney Week"	16/23/16	CI
Abionyx Pharma: capital increase completed	06/23/06	CF
ABIONYX Pharma SA Reports Earnings Results for the Half Year Ended June 30, 2023	26/23/26	CI
ABIONYX Pharma Successfully Manufactures a Second Batch of Recombinant Human ApoA-I CER-001 Using a New, Innovative and Robust Industrial Bioprocess	26/23/26	CI
Abionyx Pharma Obtains Compassionate Access Nod for Rare Kidney Disease Drug in Europe	11/23/11	MT
ABIONYX Pharma Announces New Compassionate Access Authorization for CER-001 in the Rare Disease LCAT Deficiency or Norum Disease in Europe	10/23/10	CI
ABIONYX Pharma Announces Successful Manufacturing of the First Batch of CER-001 with Recombinant Human ApoA-I Using aNew Innovative and Robust Industrial Bioprocess	10/23/10	CI
ABIONYX Pharma SA Announces New Positive Preclinical Results for the Deployment of Two Innovative Technology Platforms: Apotherapy and Biovectorization	31/23/31	CI
Global markets live: Airbus, Manchester United, EA, Credit Suisse, Warner...	30/23/30
ABIONYX Pharma SA Reports Earnings Results for the Full Year Ended December 31, 2022	29/23/29	CI
ABIONYX Pharma Reports Positive Results from Phase 2A Pilot Clinical Trial	16/23/16	CI
ABIONYX Pharma SA Announces Final Patient Enrollment in Phase 2a Clinical Trial with CER-001, Bio-HDL for the Treatment of Patients with Sepsis at High Risk of Developing Acute Kidney Injury	04/22/04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ABIONYX Pharma Börse Stuttgart

Equities

609

FR0012616852

Highlights

Filters